CLINICAL TRIALS AND OBSERVATIONS Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

نویسندگان

  • Anja Möricke
  • Alfred Reiter
  • Martin Zimmermann
  • Helmut Gadner
  • Martin Stanulla
  • Michael Dördelmann
  • Lutz Löning
  • Rita Beier
  • Wolf-Dieter Ludwig
  • Richard Ratei
  • Jochen Harbott
  • Joachim Boos
  • Georg Mann
  • Felix Niggli
  • Andreas Feldges
  • Günter Henze
  • Karl Welte
  • Jörn-Dirk Beck
  • Thomas Klingebiel
  • Charlotte Niemeyer
  • Felix Zintl
  • Udo Bode
  • Christian Urban
  • Helmut Wehinger
  • Dietrich Niethammer
  • Hansjörg Riehm
چکیده

Anja Möricke,1 Alfred Reiter,2 Martin Zimmermann,3 Helmut Gadner,4 Martin Stanulla,3 Michael Dördelmann,5 Lutz Löning,6 Rita Beier,7 Wolf-Dieter Ludwig,8 Richard Ratei,8 Jochen Harbott,2 Joachim Boos,9 Georg Mann,4 Felix Niggli,10 Andreas Feldges,11 Günter Henze,12 Karl Welte,3 Jörn-Dirk Beck,13 Thomas Klingebiel,14 Charlotte Niemeyer,15 Felix Zintl,16 Udo Bode,17 Christian Urban,18 Helmut Wehinger,19 Dietrich Niethammer,20 Hansjörg Riehm,3 and Martin Schrappe,1 for the German-Austrian-Swiss ALL-BFM Study Group

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standardrisk acute lymphoblastic leukemia (ALL) after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enroll...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study

We assessed the outcome of children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) receiving contemporary risk-based therapy by evaluating clinical and biologic features and outcome of children with ALL, with or without DS, enrolled in Children’s Cancer Group (CCG) protocols between 1983 and 1995. Comparison of characteristics of children with ALL with (ALL-DS; n 179) or without...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis

Allogeneic stem cell transplantation (SCT) is frequently considered as treatment for relapsed childhood acute lymphoblastic leukemia (ALL). For patients without a matched sibling donor, SCT from unrelated donors (UD-SCT) has been increasingly performed during the past years. However, UD-SCT–related mortality and morbidity is still considerable, and the question remains as to which patients are ...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II

One hundred ninety-eight children and adolescents were entered in the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-ALL95 study for highrisk acute lymphoblastic leukemia (ALL). Inclusion criteria were poor response to initial prednisone/intrathecal methotrexate (prednisone-poor response [PPR]), resistance to induction therapy, translocation t(9;22), infants with the t(4;11...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias

The translocation (9;22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph ) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2008